Anti-Retroviral Therapy for Alzheimer’s Disease (ART-AD)
*This study is now fully enrolled and no additional subjects are currently being recruited.
ART-AD
Purpose of this Study
The purpose of this pilot study is to evaluate if 3TC is safe and effective in preventing the development of deterioration and loss of function in the nervous system (neurodegeneration) in adults with early Alzheimer’s Disease (AD). 3TC is also known as Lamivudine and Epivir® and is an antiretroviral medication used to treat HIV and hepatitis B.
You may qualify if you are:
- Aged between 50-99 years old
- Have a clinical diagnosis of early Alzheimer’s disease
- Have a reliable caregiver that will accompany you to study visits
You may NOT qualify if you:
- Have poorly controlled high blood pressure
- History of kidney failure
- History of liver failure
Duration of the Study
The study involves 8 study visits over the course of approximately 6-7 months.
Study Procedures
- Medical history
- Physical exam
- Blood tests
- Cognitive assessment
- Urinalysis
- Spinal tap
- Questionnaires
Study Location
UT Health San Antonio
Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases
7703 Floyd Curl Drive
San Antonio, TX 78229
Sam and Ann Barshop Institute for Longevity and Aging Studies
4939 Charles Katz Dr.
San Antonio, TX 78229
Compensation
Up to $350
Clinical Research Team
Principal Investigator:
Bess Frost, PhD
Co-Principal Investigator:
Campbell Sullivan, PsyD
Co-Principal Investigator:
Nicolas Musi, MD
